Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients.
el-Ghoroury
M
M
University of Cincinnati Medical Center, Ohio, USA.
Hariharan
S
S
Peddi
V R
VR
Munda
R
R
Schroeder
T J
TJ
Demmy
A M
AM
Alexander
J W
JW
First
M R
MR
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
D000961:Antilymphocyte Serum; D001379:Azathioprine; D001786:Blood Glucose; D002096:C-Peptide; D003404:Creatinine; D016572:Cyclosporine; D006442:Glycated Hemoglobin; D007166:Immunosuppressive Agents; D008775:Methylprednisolone; D016853:Muromonab-CD3; D016559:Tacrolimus